



1st ESDO - BGDO MASTERCLASS INNOVATION IN GI CANCERS



OCTOBER 6-7, 2017

IRISH COLLEGE
www.leuveninstitute.eu

LEUVEN, BELGIUM

The Scientific Committee:

Eric Van Cutsem	ESDO President, BGDO past president	Belgium
Ivan Borbath	BGDO President	Belgium
Thomas Seufferlein	ESDO Secretary General	Germany
Jean-Luc Van Laethem	ESDO Education Committee, BGDO board	Belgium

Faculty :

Regina Beets-Tan	Netherlands	Murielle Mauer	Belgium
Ivan Borbath	Belgium	Markus Moehler	Germany
Pierre Coulie	Belgium	Patrick Pauwels	Belgium
Christophe De Roose	Belgium	Marc Peeters	Belgium
Elleke Dresen	Belgium	Wolff Schmiegel	Germany
Karen Geboes	Belgium	Max Seidensticker	Germany
Ulrich Gueller	Switzerland	Magali Svrcek	France
Aline Hebrant	Belgium	Julien Taieb	France
Alain Hendlisz	Belgium	Eric Van Cutsem	Belgium
Côme Lepage	France	Jean-Luc Van Laethem	Belgium

Organization & Registration:

Liz Tanzer info@esdo.eu tel. +43 676 7076079
ESDO c/o Vienna Medical Academy
1090 Vienna | Alser Strasse 4

Onsite Organization & Accreditation:

Anne-Sophie Wirtz management@bgdo.org
BGDO tel. + 32 476 312 411
1930 Zaventem, Leuvensesteenweg 643 b 8

PROGRAMME: INNOVATION IN GI CANCERS

FRIDAY 6 October 2017

09:00 Advances in Immuno-Oncology in GI Cancer

Chairs: Thomas Seufferlein, Ulm and Eric Van Cutsem, Leuven

- ✦ Understanding immune mechanisms in cancer and how to interfere?
 - ▲ Basic mechanisms Pierre Coulie, Brussels
 - ▲ Clinical mechanisms of action Markus Moehler, Mainz
- ✦ Clinical trials in GI cancer Julien Taieb, Paris
- ✦ Design and interpretation of trials: hurdles, requirements and conditions (round table discussion)

11:15 BREAK

11:30 Statistics for the Clinicians

Chairs: Marc Peeters, Antwerp and Côme Lepage, Dijon

- ✦ General principles Ulrich Gueller, St. Gallen
- ✦ Innovative design of trials in the era of targeted agents Murielle Mauer, EORTC – Brussels

13:00 LUNCH

14:00 Clinical Relevance of New Targets and of Molecular Taxonomy in GI Cancer

Chairs: Wolf Schmiegel, Bochum and Karen Geboes, Gent

- ✦ Gastric cancer: new targeted agents Eric Van Cutsem, Leuven
- ✦ Pancreatic cancer:
 - ▲ molecular classification Jean-Luc Van Laethem, Brussels
 - ▲ how do we progress with new agents in the clinic? Thomas Seufferlein, Ulm
- ✦ Molecular alterations in hepatocellular carcinoma: from malignant transformation to therapeutic targets Ivan Borbath, Brussels

16:00 BREAK

16:15 Technology platforms for Molecular Drugs: how to apply this in clinical practice

Chairs: Thomas Seufferlein, Ulm and Patrick Pauwels, Antwerp

- ✦ Technology Platforms for Molecular Drugs: how to apply this in clinical practice? Aline Hebrant, WIV- Belgian Cancer Centre, Brussels

PROGRAMME: INNOVATION IN GI CANCERS

- ✦ Liquid biopsies Wolff Schmiegel, Bochum
- ✦ New insights in MSI testing:
from a pathologist's point of view Magali Svrcek, Paris

17:30 END of DAY 1

SATURDAY 7 October 2017

09:00 Functional imaging in GI cancer

Chairs: Alain Hendlisz, Brussels and Ulrich Gueller, St. Gallen

- ✦ The role of MRI in response evaluation Elleke Dresen, Leuven
- ✦ Optimizing MRI in rectal cancer Regina Beets-Tan, Amsterdam
- ✦ Response evaluation after loco-regional therapy Max Seidensticker, Magdeburg
- ✦ The role of PET/CT in functional evaluation Christophe Deroose, Leuven

11:15 BREAK

11.45 Innovation and Clinical practise

Chairs: Eric Van Cutsem, Leuven and Ivan Borbath, Brussels

- ✦ The impact of epidemiologic studies in GI cancer Côme Lepage, Dijon
- ✦ Molecular Tumor Board : Clinical case discussion Panel: TBC
- ✦ Conclusion: Future innovations in GI Cancer Eric Van Cutsem &
Thomas Seufferlein

13:00 END



MERCK

SIRTeX



SUPPORTING PARTNERS